Hikal share news, announcements and annual reports
NSE: HIKALBSE: 524735Pharmaceuticals & BiotechnologySmall Cap
Hikal Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jan 1995 on BSE, Feb 2001 on NSE
Last close ₹204.40up ₹2.30 (1.14%)BSE ₹204.75
Share price at the NSE close on 29 Oct 2026. Previous close ₹202.10.
29 Oct: open ₹202.21, high ₹206.02, low ₹201.61
52-week range of traded prices to 29 Oct 2026
₹146.25Low, 30 Mar 2026₹261.00High, 4 Dec 2025
- Next results date: the board meets on 3 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹2,520 Cr1,090th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.10
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.29%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- −2.7%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹76 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 3.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 3.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.57
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 1,47,46136.8% delivered
Hikal disputes and clarifications
14 filed, newest first.
Apr 2026
Jan 2026
7 Jan · Legal
Exchange has sought clarification from Hikal Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted in XBRL with discrepancies The response of the Company is awaited.
Dec 2025
26 Dec · Legal
Mar 2023
16 Mar · Legal
The exchange asked on 15 Mar 2023
Dec 2022
30 Dec · Legal
The exchange asked on 30 Dec 2022
7 Dec · Legal
The exchange asked on 7 Dec 2022
May 2022
25 May · Legal
The exchange asked on 24 May 2022
Feb 2022
18 Feb · Legal
Exchange has sought clarification from Hikal Limited with respect to announcement dated 16-Feb-2022, regarding receipt of notice from the Maharashtra Pollution Control Board for closure of theCompany s Manufacturing Unit located at MIDC Taloja, Dist. Raiga. On basis of above the Company is required to clarify following: 1. Expected financial implications, if any, due to compensation, penalty etc;2. Quantum of claims, if any3. Expected quantum of loss/damage caused;The response of the Company is awaited.
Apr 2021
7 Apr · Legal
The exchange asked on 1 Apr 2021
Mar 2020
9 Mar · Legal
Exchange has sought clarification from Hikal Limited with respect to announcement dated 06-Mar-2020, regarding closure of Mahad Unit based on a complaint received from the local community in Taloja. On basis of above the Company is required to clarify following: 1. Amount & percentage of turnover or revenue or income and net worth of the listed entity contributed by such unit or division during the last financial year; 2. Date of closure or estimated time of closure; The response of the Company is awaited.
Nov 2019
19 Nov · Legal
Exchange has sought clarification from Hikal Limited with respect to announcement dated 28-Oct-2019, regarding 'Update on plant operations of the Company'. On basis of above the Company is required to clarify following: 1. The actual amount of damage caused due to the natural calamity or other force majeure events;2. Details of steps taken to restore normalcy and the impact of the natural calamity/other force majeure events on production or service, financials of the entityThe response of the Company is awaited.
Sep 2007
25 Sep · Legal
September 25, 2007 that "Regarding The Hindu Business Line article entitled "Pfizer gets relief on epilepsy drug as US court reverses ruling". With reference to the above-mentioned article which has appeared today, Hikal would like to state that it is neither in the finished formulation business nor does it market finished dosage forms in the US. In addition Hikal has consulted its attorneys who have confirmed that Hikal has sound patent situation. Initial communication with our customers indicate that there would be no interruptions for the supply of Gabapentin from Hikal and that they are not affected by the recent judgment of the US courts. We except it to be business as usual for Hikal and its supply of Gabapentin".